Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion
19 hours ago
Eli Lilly has agreed to acquire Calytrix Bio for up to $1.5 billion to expand its rare blood cancer treatment pipeline. This acquisition strengthens Lilly's hematology portfolio and diversifies revenue beyond its diabetes and weight-loss franchises.
2026-02-03
Feb. 3 Business Watch: Catalysis start-ups raise money; Lilly strikes deals with 2 biotech firms2026-04-30
Lilly lifts profit forecast as surging demand for weight-loss drugs offsets pricing pressure2026-04-30
US Premarket Movers for April 30, 20262026-05-21
US Premarket Movers for May 21, 2026Show all 24 updates